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The presence of persistent intrathecal oligoclonal immunoglobulin G (IgG) bands (OCBs)
and lesional IgG deposition are seminal features of multiple sclerosis (MS) disease
pathology. Despite extensive investigations, the role of antibodies, the products of
mature CD19+ B cells, in disease development is still controversial and under significant
debate. Recent success of B cell depletion therapies has revealed that CD20+ B
cells contribute to MS pathogenesis via both antigen-presentation and T-cell-regulation.
However, the limited efficacy of CD20+ B cell depletion therapies for the treatment of
progressive MS indicates that additional mechanisms are involved. In this review, we
present findings suggesting a potential pathological role for increased intrathecal IgGs,
the relation of circulating antibodies to intrathecal IgGs, and the selective elevation of IgG1
and IgG3 subclasses in MS. We propose a working hypothesis that circulating B cells
and antibodies contribute significantly to intrathecal IgGs, thereby exerting primary and
pathogenic effects in MS development. Increased levels of IgG1 and IgG3 antibodies
induce potent antibody-mediated cytotoxicity to central nervous system (CNS) cells
and/or reduce the threshold required for antigen-driven antibody clustering leading
to optimal activation of immune responses. Direct proof of the pathogenic roles of
antibodies in MS may provide opportunities for novel blood biomarker identification as
well as strategies for the development of effective therapeutic interventions.
Keywords: multiple sclerosis, antibody, oligoclonal bands, immunoglobulin G, cytotoxicity, cerebrospinal fluid,
serum, B cells
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous system
(CNS), especially the brain, spinal cord, and optic nerves. About 1 million people in the US and
2.5 million worldwide live with a diagnosis of MS (1). After its first description in 1868 by Jean-
Martin Charcot, MS has been classified into different types such as clinically isolated syndrome
(CIS, a clinical syndrome highly suggestive of a first manifestation of MS), relapsing remitting
(RR), secondary progressive (SP), and primary progressive (PP) (2). Extensive pathological studies
have classified MS lesions as active, chronic active, inactive, and pre-active stages (3). Despite the
heterogeneous features of MS lesions, a consensus has emerged that the pathogenic mechanisms
of the disease are contributed by CNS inflammation and infiltration of peripheral immune cells,
resulting in neuronal and glial cell injury and subsequent loss of myelin sheath around nerves,
interruption of axonal communication, and neurologic deficits (4). However, the exact cause of MS
is unknown, and currently there is no cure for the disease.
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The presence of persistent CNS oligoclonal immunoglobulin
G (IgG) bands (OCBs) and lesional IgG deposition are hallmarks
of MS. OCBs consist of clonally restricted immunoglobulins
detected by isoelectric focusing (IEF) and are a key feature of
ongoing inflammatory events in CNS in a number of neuro-
inflammatory conditions and viral infections (5). Although the
pathological effects of OCBs have been implicated since their
discovery (6), the role of antibodies in the pathogenesis of
MS is controversial. In this review, we discuss pathological
and immunological studies regarding the role of antibodies in
MS. We propose a novel framework regarding the pathogenic
mechanism of disease, which could be mediated by increased
levels of serum IgG1 and IgG3 antibodies.
INCREASED INTRATHECAL SYNTHESIS
OF OCB IS THE MOST CHARACTERISTIC
FEATURE OF MS
Early biochemical studies ofMS autopsy brain plaques with active
lesions have demonstrated the presence of excessive amounts of
IgG antibodies in both free/soluble and tissue-bound/particulate
forms (7–9). The IgGs extracted from corresponding soluble and
particulate samples displayed OCBs (9). Extensive pathological
characterization of heterogeneous MS autopsy brain samples has
demonstrated the co-localization of IgG antibodies, complement,
and Fc gamma receptors (FcγR) in the active lesions, suggesting
a role for these antibodies in the early stages of the disease
(10, 11). Furthermore, complement activation is found in PPMS
cortical gray matter lesions (12), indicating that antibodies
may contribute to the worsening pathology that underlies the
irreversible progression of MS. These lines of evidence suggest
that the excessive presence of IgG antibodies in MS lesions
may induce complement-mediated and immune-cell-mediated
cytotoxicity, resulting in lesion formation.
The single most consistent laboratory abnormality in MS
is the presence of OCBs in the cerebrospinal fluid (CSF) of
up to 95% of patients (13, 14). Once present, the pattern of
OCB is characteristic for each individual and does not change
within patients over years, despite therapeutic interventions
(5, 13, 15, 16). Besides OCBs, the intrathecal IgG can also be
visualized with Reiber diagram, which uses CSF/serum quotient
diagrams with hyperbolic discrimination lines for IgG (17).
Plasma cells are found in the chronically inflamed MS CNS
(18). Long-lived plasma cells were demonstrated in chronically
inflamed CNS and chemokine CXCL12 is involved in plasma
cell persistence (19). For detailed review regarding the complex
nature of resident plasma cells and mechanism driving the
persistence in CNS, please see the review by Pryce and Baker
(5). Using a phage-displayed random peptide library approach,
we demonstrated that CSF IgGs obtained longitudinally fromMS
patients recognized identical epitopes over time, supporting the
notion of a temporal stability of CSF IgG specificity (20).
Accumulating evidence supports the pathological role of
CSF immunoglobulins. CSF OCBs were found to be associated
with increased levels of disease activity and disability, with the
conversion from a CIS to early RRMS, with greater brain atrophy,
and with increased levels of disease activity (21–28). Further,
CSF of MS patients induced inflammatory demyelination and
axonal damage inmice (29, 30).We demonstrated that a subset of
myelin-specific recombinant antibodies constructed from clonal
expanded plasma cells in MS CSF caused robust complement-
dependent cytotoxicity in oligodendrocytes and induced rapid
demyelination in mouse organotypic cerebellar slices (31, 32).
These studies support the pathogenic effects of CSF IgGs in
MS. Despite the significance of OCB in MS, no statistically
significant differences of both number of OCBs and IgG index
were found among subtypes of MS (CIS, RRMS, PPMS, and
SPMS) (33). New technologies such as recombinant antibodies
generated from clonally expanded single B cells/plasma cells and
directly from IgG sequences of OCBs provided promises for
determining the specificities of OCB, but have so far failed to
reveal a common targets ofMS (34–37) (https://www.jni-journal.
com/article/S0165-5728(20)30298-8/pdf).
Except for myelin, convincing CNS target antigens for OCBs
that are specific toMS are not known. Recently, it was shown that
some OCBs targeted ubiquitous self-proteins and intracellular
antigens (37–39), suggesting that CSF antibodies may develop as
a passive response to CNS injury, rather than mediating primary
pathogenic effects. Besides MS, CSF OCBs have been reported in
a number of neuro-inflammatory conditions and viral infections
(40). It has been argued that this intrathecal, poly-specific, and
oligoclonal immune response possibly indicates that it is not a
specific antigen that drives the development of OCBs in MS, but
rather a non-specific activation of CSF-localized B cells (41).
THE SOURCES OF INCREASED
INTRATHECAL IgG, A CONTROVERSY IN
MS
Correlation of Serum Antibodies With
Intrathecal IgGs
OCBs are thought to be produced by intrathecal parenchymal B
lymphocytes, as the CSF Ig proteome and transcriptome of CSF-
located B cells matched each other. In addition, intrathecal B
cells show signs of somatic hyper-mutation and clonal expansion,
pointing toward a germinal center-like reaction with antigen-
driven affinity maturation within the CNS (42, 43). However,
there is new evidence that terminally differentiated B cells in
MS CSF are not solely derived from intrathecal maturation,
but can emerge from the CNS compartment and interact with
the peripheral immune system (44–46). Recent deep-immune
repertoire studies revealed that MS CSF OCBs were not merely
produced by CNS B cells, and someOCB specificities were related
only to peripheral B cells, which indicate that disease-relevant
B cells circulate between the CNS and peripheral compartments
(47). We recently demonstrated that serum IgG in MS was
significantly elevated and there was a strong correlation between
CSF IgG and CSF albumin, and also between CSF IgG and serum
IgG (48). Since CSF albumin is exclusively derived from the blood
in MS, this correlation suggests that most of the CSF IgG is
derived from the blood. It has to be noted that about 50% of
MS sera did not show OCBs and patients with OCBs in sera
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had patterns either partially similar or completely different from
those seen in matching CSF (49). Because serum IgG is about 200
times more concentrated than CSF IgG (48), it is possible that
serum OCBs are masked by massive amounts of polyclonal IgGs.
Another line of evidence supporting serum and intrathecal
IgG exchange comes from the discrepancy between number of
CNS B cells and the quantities of intrathecal IgG. A careful
examination of MS plaques concluded that there were far too
few cells in the plaques to contribute to IgG (50). As calculated
by Tourtellotte’s formula, the normal values of the CNS IgG
synthesis rate were lower than 3.3 mg/day and the median value
in MS patients was 29 mg/day (51). It would take 3.2 billion
lymphocytes in MS to generate such large amounts of CNS IgG
(30mg in 500ml CSF) (52). We and others have demonstrated
that CSF leukocyte counts in most MS patients were <50 cells/µl
(about 2.5 million cells in 500ml CSF), of which 5% were B
cells (48, 53, 54). Therefore, CSF lymphocytes could only account
for <0.1% of the IgG in the MS CSF per day. The low number
of lymphocytes in MS CSF and the high level of intrathecal
IgG raise the question as to whether CNS B cells in MS can
be responsible for the massive amounts of elevated intrathecal
IgG. This apparent knowledge gap suggests that most of the
intrathecal IgG in MS may in fact be derived from the blood.
MRI Detection of the Central Vein Sign in
MS Lesions Supports a Peripheral Blood
Contribution to Disease Activity
Early histopathological studies detected a unique character of MS
lesions described as “centrifugally-spreading” that an MS plaque
did not spread or grow at its edges. Plaques began as collars of
demyelination around small veins and enlarged thereafter (50).
This perivenous distribution of MS plaques was confirmed by
ultra-high-field magnetic resonance imaging (MRI) (55–57). The
MRI-detectable central vein sign inside white matter lesions can
distinguish MS from other CNS inflammatory disorders and has
been proposed as a biomarker for inflammatory demyelination
(58). Further, the serum protein fibrinogen was found frequently
and extensively to be present diffusely in both extracellular
and intracellular spaces of MS motor cortex and in close
proximity to blood vessels, and was related to the extent of
neurodegeneration in progressive forms of MS (59). This line of
evidence supports the notion of peripheral blood contribution of
B cells and antibodies to intrathecal IgGs and their potential role
in disease development.
We propose that MS intrathecal IgGs are derived from B
cells in both the CNS and peripheral blood and may thus be
contributed by serum antibodies (Figure 1). Inside the CNS
compartments, clonally expanded antigen-experienced plasma
cells produce antibodies that may target cell surface antigens and
exert a pathogenic effect by activating complement-dependent or
immune-cell dependent cytotoxicity. A subpopulation of these
antibodies may direct against intracellular autoantigens released
during tissue destruction. On the other hand, serum B cells
and antibodies migrate across the blood barriers either by active
transportation or by barrier breakdown. Some of these serum
antibodies in MS are clearly pathogenic as reviewed below.
CIRCULATING ANTIBODIES CONTRIBUTE
TO MS DISEASE PATHOGENESIS
Pathogenic Effect of Serum Antibodies
The benefit shown in therapeutic plasma exchange and immune-
adsorption therapy in some MS patients (41, 60, 61) suggests
that serum antibodies in MS are pathogenic. Patients who had
lesions with prominent Ig deposition and complement activation
profited most from plasma exchange (60, 62). However, direct
proof of the pathogenic role of serum antibody in MS is
complicated by the marked heterogeneity of the disease and the
variability of experimental procedures.
Early in vitro demyelination studies have provided evidence
supporting a pathogenic role of serum antibodies (50) and
that there is strong correlation between disease activity and
demyelinative activity of MS serum. Lumsden (50) investigated
sera from 450MS patients and controls over 7 years with
1,300 tests. He found that over 80% of MS sera with natural
complement produced demyelination in live cultures of newborn
rat cerebellum. Further, he found patients’ immunoglobulins
and complement were fixed anti-mortem to CNS components,
indicating that circulating antibody in MS binds to myelin
and causes demyelination. Lumsden’s data indicate that serum
antibodies in their natural state are pathogenic when they
penetrate the CNS parenchyma. Using ex vivo assays, a number
of laboratories have reported that some MS patients have
serum factors that demyelinate myelinating explants (63–66).
Later, complement-dependent demyelinating IgG response was
detected with purified serum IgGs in ∼30% of 37MS patients
(67). However, the demyelinating effect of MS serum IgGs has
been controversial, which is due in part to variable tissue culture
and myelin imaging methods. Additionally, we postulate that the
different results may reflect the sources of antibodies used. The
antibody purification procedures may result in loss of the natural
state of antibodies and may fail to efficiently recover specific IgG
subclasses, resulting in a substantial reduction or a complete loss
of demyelinating effect. Lumsden’s work was carried out using
unpurified native serum antibodies (50).
The potential pathogenic role of serum antibodies may also
extend to enhancing inflammatory responses across the BBB in
MS. For example, significantly higher levels of anti-endothelial
cell antibodies and immune complexes were found in MS sera
(68), and serum antibodies from MS patients were detected in
micro-vessels in brain tissues and bound to endothelia cells (69,
70). Further, sera from RRMS and SPMS disrupt the BBB (71).
In summary, over 50 years of extensive scientific investigations
have provided accumulating evidence that serum antibodies in
their natural state exert primary antibody-dependent cytotoxicity
to glial cells, which leads to demyelinating effects that could
contribute to MS disease pathogenesis.
Insights From B Cell Depletion Therapies
B cell depletion therapies using monoclonal antibodies against
CD20; namely, Rituximab, Ocrelizumab, and Ofatumumab have
shown profound success in controlling MS relapses (41). CD20
is a four-transmembrane protein expressed on the surface of
B cells from the late pro-B cells through the memory cell
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FIGURE 1 | Model of the role of serum antibodies in MS disease pathogenesis. Circulating serum antibodies (IgG1 and IgG3, purple) and antibody-producing B cells
migrate across the impaired blood-barrier (arrow), and they are present in CSF OCBs and CNS lesion together with intrathecal IgGs (IgG1 and IgG3, turquoise). In the
brain, IgGs recognize antigens on the cell surfaces of neurons or/and glial cells and form immune complexes with complement factors and/or immune cells. Elevated
levels of IgG1 and IgG3 induce enhanced cytotoxicity or reduced threshold to trigger injury response to CNS cells, which, in turn, result in loss of myelin sheath
outside of axons. BCSFB, blood-CSF barrier.
stages, but not on antibody-producing plasma cells. Thus, the
efficacy of this B cell depletion therapy has been considered
to be mediated by B cell function independent of antibody
production, such as antigen-presentation for the activation of
T cells and pro-inflammatory cytokine secretion (72). Indeed,
serum antibody level and CSF OCB often persist despite CD20-
antibody depleting B cells (5, 73). In some instances, certain
serum antibodies were reduced in a proportion of patients after
intravenous Rituximab treatment (74). CSF plasma cell depletion
was observed following repeated intrathecal Rituximab injection
(75, 76). These reductions are thought to result from secondary
effects such as depletion of plasma cell precursors, depletion
of survival factors, or possibly destruction of B cell niches
rather than a direct influence on plasma cells. Interestingly,
Laquinimod, a T cell targeting oral disease-modifying therapy,
has been shown to modulate myelin antigen-specific B cell
immune response and inhibit development of MOG-specific IgG
antibodies (77). And treatment of Cladribine (another T cell
targeted drug) in MS is associated with depletion of memory B
cells (78).
However, reports of MS patients’ failure to respond to anti-
CD20 therapies, or even disease exacerbation thereafter, have
also been published. Anti-CD20 therapies have limited efficacy
in inhibiting disease progression (41). It is possible that these
therapies do not effectively target the antibody-producing B cells,
or do not significantly reduce the antibody levels in serum and
CSF. Another issue concerns the increased risk of infection that is
likely to accumulate with continuous B cell depletion with time.
In MS, only a fraction of B cells and antibodies are pathogenic,
while other subsets of B cells and antibodies exert essential
regulatory functions to limit chronic inflammation. For in-depth
reviews regarding B cell therapies and B cell biology between
subtypes of MS, please see review papers by Gelfand et al. (79),
Fraussen et al. (80), andMyhr et al. (81). It will be very important
to develop innovative strategies selectively abrogating pathogenic
B cells and antibodies. Thus, identifying the specific features of
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pathogenic antibodies in MS is crucial for the development of
successful therapeutic interventions.
ELEVATED LEVELS OF IgG1 AND IgG3
ANTIBODIES IN CSF AND SERUM, AN MS
SPECIFIC FEATURE
Selective Elevation of IgG1 and IgG3 in MS
The glycoprotein IgG can be separated into four subclasses: IgG1
(60–70% in plasma), IgG2 (20–30%), IgG3 (5–8%), and IgG4
(1–3%) (82). A selective elevation of the IgG1 in MS CSF was
observed (83, 84). The elevation of IgG1 and IgG3 indices in
MS were found more frequently than the elevation of the general
IgG index (21). Patients with a relapse were significantly more
frequently seropositive for anti-MOG and anti-MBP IgG3 than
those in remission (85). Further, the IgG3 allotype G3m was
MS-specific and present in active brain plaques (86). Subsequent
studies demonstrated that the susceptibility to MS was associated
with an IgG3 restriction fragment length polymorphism (87),
and a GWAS study showed that intrathecal IgG synthesis in
MS was significantly associated with the intronic region of the
IgG3 heavy chain gene SNPs (88). The significance of IgG3 in
MS was recently highlighted by a findings that higher serum
IgG3 levels may predict the development of MS from CIS (89)
and IgG3 + B cells are associated with the development of MS
(90). These data suggest that the presence of higher levels of
IgG1 and IgG3 antibodies may play a significant role in MS
disease activity.
Increased IgG1 and IgG3 Enhances
Effector Functions
IgG3 has an extended hinge region with highest flexibility
compared to other antibody subclasses. This subclass can
probe less exposed antigens. This feature could contribute
to the higher potential of IgG3, followed by IgG1, to
antibody oligomerization and activation of effector functions,
including enhanced antibody-mediated cellular cytotoxicity
(ADCC); opsonophagocytosis; complement activation; and
neutralization. Additionally, IgG3 has superior affinity to
FcγR and the first component of complement cascade,
C1q (78). Thus, increased IgG1 and IgG3 in MS serum
and CSF may enhance immune-mediated cytotoxicity
to CNS cells or may reduce the thresholds for antigen-
driven antibody clustering for optimal activation of
immune responses.
CONCLUSIONS
The role of antibodies in MS disease mechanisms has been
disputed over several decades due to the lack of direct
and reproducible proof of pathogenic effects. The limited
efficacy of CD20-B cell therapies in progressive MS patients
and in controlling disease progression implicates that CD20-
negative antibody-producing B cells, as well as antibodies,
play an important role in disease pathogenesis. The combined
accumulating data that there is a strong correlation between
serum and CSF IgG, insufficient B cells to produce large
quantities of intrathecal IgG, MRI detection of the central
vein sign in MS, and presence of pathogenic serum antibodies
provide evidence for the hypothesis that circulating antibodies
contribute to increased intrathecal IgG synthesis in MS. We
further propose that (1) serum antibodies exert primary and
pathogenic effects in MS development; (2) increased IgG1 and
IgG3 result in enhanced cytotoxicity to CNS cells and produce
antibody-mediated injury in MS pathogenesis (Figure 1). This
novel hypothesis may help to resolve the current controversy
regarding the roles of antibodies in MS and may draw attention
to the possibly pathogenic role of IgG3. It may also provide
novel opportunities for blood biomarker identification and the
development of effective therapeutic interventions for MS.
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